Table of Content

1 Biosimilars Market Overview
1.1 Product Overview and Scope of Biosimilars
1.2 Biosimilars Segment by Type
1.2.1 Global Biosimilars Market Value Comparison by Type (2024-2034)
1.2.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
1.2.3 Recombinant Glycosylated Proteins
1.3 Biosimilars Segment by Application
1.3.1 Global Biosimilars Market Value by Application: (2024-2034)
1.3.2 Oncology
1.3.3 Blood Disorders
1.3.4 Growth Hormonal Deficiency
1.3.5 Chronic and Autoimmune Disorders
1.3.6 Others
1.4 Global Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Biosimilars Revenue 2018-2034
1.4.2 Global Biosimilars Sales 2018-2034
1.4.3 Global Biosimilars Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Biosimilars Market Competition by Manufacturers
2.1 Global Biosimilars Sales Market Share by Manufacturers (2018-2023)
2.2 Global Biosimilars Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Biosimilars Average Price by Manufacturers (2018-2023)
2.4 Global Biosimilars Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilars, Product Type & Application
2.7 Biosimilars Market Competitive Situation and Trends
2.7.1 Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilars Players Market Share by Revenue
2.7.3 Global Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilars Retrospective Market Scenario by Region
3.1 Global Biosimilars Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Biosimilars Global Biosimilars Sales by Region: 2018-2034
3.2.1 Global Biosimilars Sales by Region: 2018-2023
3.2.2 Global Biosimilars Sales by Region: 2024-2034
3.3 Global Biosimilars Global Biosimilars Revenue by Region: 2018-2034
3.3.1 Global Biosimilars Revenue by Region: 2018-2023
3.3.2 Global Biosimilars Revenue by Region: 2024-2034
3.4 North America Biosimilars Market Facts & Figures by Country
3.4.1 North America Biosimilars Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Biosimilars Sales by Country (2018-2034)
3.4.3 North America Biosimilars Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Biosimilars Market Facts & Figures by Country
3.5.1 Europe Biosimilars Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Biosimilars Sales by Country (2018-2034)
3.5.3 Europe Biosimilars Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilars Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Biosimilars Sales by Country (2018-2034)
3.6.3 Asia Pacific Biosimilars Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Biosimilars Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Biosimilars Sales by Country (2018-2034)
3.7.3 Latin America Biosimilars Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilars Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Biosimilars Sales by Country (2018-2034)
3.8.3 Middle East and Africa Biosimilars Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilars Sales by Type (2018-2034)
4.1.1 Global Biosimilars Sales by Type (2018-2023)
4.1.2 Global Biosimilars Sales by Type (2024-2034)
4.1.3 Global Biosimilars Sales Market Share by Type (2018-2034)
4.2 Global Biosimilars Revenue by Type (2018-2034)
4.2.1 Global Biosimilars Revenue by Type (2018-2023)
4.2.2 Global Biosimilars Revenue by Type (2024-2034)
4.2.3 Global Biosimilars Revenue Market Share by Type (2018-2034)
4.3 Global Biosimilars Price by Type (2018-2034)
5 Segment by Application
5.1 Global Biosimilars Sales by Application (2018-2034)
5.1.1 Global Biosimilars Sales by Application (2018-2023)
5.1.2 Global Biosimilars Sales by Application (2024-2034)
5.1.3 Global Biosimilars Sales Market Share by Application (2018-2034)
5.2 Global Biosimilars Revenue by Application (2018-2034)
5.2.1 Global Biosimilars Revenue by Application (2018-2023)
5.2.2 Global Biosimilars Revenue by Application (2024-2034)
5.2.3 Global Biosimilars Revenue Market Share by Application (2018-2034)
5.3 Global Biosimilars Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Biosimilars Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Biocon
6.3.1 Biocon Corporation Information
6.3.2 Biocon Description and Business Overview
6.3.3 Biocon Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biocon Biosimilars Product Portfolio
6.3.5 Biocon Recent Developments/Updates
6.4 Biogen
6.4.1 Biogen Corporation Information
6.4.2 Biogen Description and Business Overview
6.4.3 Biogen Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Biogen Biosimilars Product Portfolio
6.4.5 Biogen Recent Developments/Updates
6.5 Fresenius Kabi AG
6.5.1 Fresenius Kabi AG Corporation Information
6.5.2 Fresenius Kabi AG Description and Business Overview
6.5.3 Fresenius Kabi AG Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Fresenius Kabi AG Biosimilars Product Portfolio
6.5.5 Fresenius Kabi AG Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boehringer Ingelheim Biosimilars Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Merck KgaA
6.6.1 Merck KgaA Corporation Information
6.6.2 Merck KgaA Description and Business Overview
6.6.3 Merck KgaA Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck KgaA Biosimilars Product Portfolio
6.7.5 Merck KgaA Recent Developments/Updates
6.8 Mylan
6.8.1 Mylan Corporation Information
6.8.2 Mylan Description and Business Overview
6.8.3 Mylan Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Mylan Biosimilars Product Portfolio
6.8.5 Mylan Recent Developments/Updates
6.9 Eli Lilly
6.9.1 Eli Lilly Corporation Information
6.9.2 Eli Lilly Description and Business Overview
6.9.3 Eli Lilly Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Eli Lilly Biosimilars Product Portfolio
6.9.5 Eli Lilly Recent Developments/Updates
6.10 Teva Pharmaceutical
6.10.1 Teva Pharmaceutical Corporation Information
6.10.2 Teva Pharmaceutical Description and Business Overview
6.10.3 Teva Pharmaceutical Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Teva Pharmaceutical Biosimilars Product Portfolio
6.10.5 Teva Pharmaceutical Recent Developments/Updates
6.11 Dr. Reddy's Laboratories
6.11.1 Dr. Reddy's Laboratories Corporation Information
6.11.2 Dr. Reddy's Laboratories Biosimilars Description and Business Overview
6.11.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
6.11.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Corporation Information
6.12.2 Amgen Biosimilars Description and Business Overview
6.12.3 Amgen Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Amgen Biosimilars Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Celltrion
6.13.1 Celltrion Corporation Information
6.13.2 Celltrion Biosimilars Description and Business Overview
6.13.3 Celltrion Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Celltrion Biosimilars Product Portfolio
6.13.5 Celltrion Recent Developments/Updates
6.14 Samsung Biologics
6.14.1 Samsung Biologics Corporation Information
6.14.2 Samsung Biologics Biosimilars Description and Business Overview
6.14.3 Samsung Biologics Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Samsung Biologics Biosimilars Product Portfolio
6.14.5 Samsung Biologics Recent Developments/Updates
6.15 Roche
6.15.1 Roche Corporation Information
6.15.2 Roche Biosimilars Description and Business Overview
6.15.3 Roche Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Roche Biosimilars Product Portfolio
6.15.5 Roche Recent Developments/Updates
6.16 Probiomed
6.16.1 Probiomed Corporation Information
6.16.2 Probiomed Biosimilars Description and Business Overview
6.16.3 Probiomed Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Probiomed Biosimilars Product Portfolio
6.16.5 Probiomed Recent Developments/Updates
6.17 Apotex
6.17.1 Apotex Corporation Information
6.17.2 Apotex Biosimilars Description and Business Overview
6.17.3 Apotex Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Apotex Biosimilars Product Portfolio
6.17.5 Apotex Recent Developments/Updates
6.18 Chong Kun Dang
6.18.1 Chong Kun Dang Corporation Information
6.18.2 Chong Kun Dang Biosimilars Description and Business Overview
6.18.3 Chong Kun Dang Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Chong Kun Dang Biosimilars Product Portfolio
6.18.5 Chong Kun Dang Recent Developments/Updates
6.19 JCR Pharmaceuticals
6.19.1 JCR Pharmaceuticals Corporation Information
6.19.2 JCR Pharmaceuticals Biosimilars Description and Business Overview
6.19.3 JCR Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.19.4 JCR Pharmaceuticals Biosimilars Product Portfolio
6.19.5 JCR Pharmaceuticals Recent Developments/Updates
6.20 Gan & Lee Pharmaceuticals
6.20.1 Gan & Lee Pharmaceuticals Corporation Information
6.20.2 Gan & Lee Pharmaceuticals Biosimilars Description and Business Overview
6.20.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
6.20.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.21 Gedeon Richter
6.21.1 Gedeon Richter Corporation Information
6.21.2 Gedeon Richter Biosimilars Description and Business Overview
6.21.3 Gedeon Richter Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Gedeon Richter Biosimilars Product Portfolio
6.21.5 Gedeon Richter Recent Developments/Updates
6.22 Biocad
6.22.1 Biocad Corporation Information
6.22.2 Biocad Biosimilars Description and Business Overview
6.22.3 Biocad Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Biocad Biosimilars Product Portfolio
6.22.5 Biocad Recent Developments/Updates
6.23 Coherus Bioscience
6.23.1 Coherus Bioscience Corporation Information
6.23.2 Coherus Bioscience Biosimilars Description and Business Overview
6.23.3 Coherus Bioscience Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Coherus Bioscience Biosimilars Product Portfolio
6.23.5 Coherus Bioscience Recent Developments/Updates
6.24 Stada Arzneimittel AG
6.24.1 Stada Arzneimittel AG Corporation Information
6.24.2 Stada Arzneimittel AG Biosimilars Description and Business Overview
6.24.3 Stada Arzneimittel AG Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Stada Arzneimittel AG Biosimilars Product Portfolio
6.24.5 Stada Arzneimittel AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilars Industry Chain Analysis
7.2 Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilars Production Mode & Process
7.4 Biosimilars Sales and Marketing
7.4.1 Biosimilars Sales Channels
7.4.2 Biosimilars Distributors
7.5 Biosimilars Customers
8 Biosimilars Market Dynamics
8.1 Biosimilars Industry Trends
8.2 Biosimilars Market Drivers
8.3 Biosimilars Market Challenges
8.4 Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Biosimilars Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Biosimilars Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Biosimilars Market Competitive Situation by Manufacturers in 2024
Table 4. Global Biosimilars Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Biosimilars Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Biosimilars Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Biosimilars Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Biosimilars Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Biosimilars, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilars, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilars, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilars Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Biosimilars Sales by Region (2018-2023) & (K Units)
Table 18. Global Biosimilars Sales Market Share by Region (2018-2023)
Table 19. Global Biosimilars Sales by Region (2024-2034) & (K Units)
Table 20. Global Biosimilars Sales Market Share by Region (2024-2034)
Table 21. Global Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Biosimilars Revenue Market Share by Region (2018-2023)
Table 23. Global Biosimilars Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Biosimilars Revenue Market Share by Region (2024-2034)
Table 25. North America Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Biosimilars Sales by Country (2018-2023) & (K Units)
Table 27. North America Biosimilars Sales by Country (2024-2034) & (K Units)
Table 28. North America Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Biosimilars Sales by Country (2018-2023) & (K Units)
Table 32. Europe Biosimilars Sales by Country (2024-2034) & (K Units)
Table 33. Europe Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Biosimilars Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Biosimilars Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Biosimilars Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Biosimilars Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Biosimilars Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Biosimilars Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Biosimilars Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Biosimilars Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Biosimilars Sales (K Units) by Type (2018-2023)
Table 51. Global Biosimilars Sales (K Units) by Type (2024-2034)
Table 52. Global Biosimilars Sales Market Share by Type (2018-2023)
Table 53. Global Biosimilars Sales Market Share by Type (2024-2034)
Table 54. Global Biosimilars Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Biosimilars Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Biosimilars Revenue Market Share by Type (2018-2023)
Table 57. Global Biosimilars Revenue Market Share by Type (2024-2034)
Table 58. Global Biosimilars Price (USD/Unit) by Type (2018-2023)
Table 59. Global Biosimilars Price (USD/Unit) by Type (2024-2034)
Table 60. Global Biosimilars Sales (K Units) by Application (2018-2023)
Table 61. Global Biosimilars Sales (K Units) by Application (2024-2034)
Table 62. Global Biosimilars Sales Market Share by Application (2018-2023)
Table 63. Global Biosimilars Sales Market Share by Application (2024-2034)
Table 64. Global Biosimilars Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Biosimilars Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Biosimilars Revenue Market Share by Application (2018-2023)
Table 67. Global Biosimilars Revenue Market Share by Application (2024-2034)
Table 68. Global Biosimilars Price (USD/Unit) by Application (2018-2023)
Table 69. Global Biosimilars Price (USD/Unit) by Application (2024-2034)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Pfizer Biosimilars Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Novartis Biosimilars Product
Table 79. Novartis Recent Developments/Updates
Table 80. Biocon Corporation Information
Table 81. Biocon Description and Business Overview
Table 82. Biocon Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. Biocon Biosimilars Product
Table 84. Biocon Recent Developments/Updates
Table 85. Biogen Corporation Information
Table 86. Biogen Description and Business Overview
Table 87. Biogen Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Biogen Biosimilars Product
Table 89. Biogen Recent Developments/Updates
Table 90. Fresenius Kabi AG Corporation Information
Table 91. Fresenius Kabi AG Description and Business Overview
Table 92. Fresenius Kabi AG Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Fresenius Kabi AG Biosimilars Product
Table 94. Fresenius Kabi AG Recent Developments/Updates
Table 95. Boehringer Ingelheim Corporation Information
Table 96. Boehringer Ingelheim Description and Business Overview
Table 97. Boehringer Ingelheim Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. Boehringer Ingelheim Biosimilars Product
Table 99. Boehringer Ingelheim Recent Developments/Updates
Table 100. Merck KgaA Corporation Information
Table 101. Merck KgaA Description and Business Overview
Table 102. Merck KgaA Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Merck KgaA Biosimilars Product
Table 104. Merck KgaA Recent Developments/Updates
Table 105. Mylan Corporation Information
Table 106. Mylan Description and Business Overview
Table 107. Mylan Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Mylan Biosimilars Product
Table 109. Mylan Recent Developments/Updates
Table 110. Eli Lilly Corporation Information
Table 111. Eli Lilly Description and Business Overview
Table 112. Eli Lilly Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. Eli Lilly Biosimilars Product
Table 114. Eli Lilly Recent Developments/Updates
Table 115. Teva Pharmaceutical Corporation Information
Table 116. Teva Pharmaceutical Description and Business Overview
Table 117. Teva Pharmaceutical Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Teva Pharmaceutical Biosimilars Product
Table 119. Teva Pharmaceutical Recent Developments/Updates
Table 120. Dr. Reddy's Laboratories Corporation Information
Table 121. Dr. Reddy's Laboratories Description and Business Overview
Table 122. Dr. Reddy's Laboratories Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Dr. Reddy's Laboratories Biosimilars Product
Table 124. Dr. Reddy's Laboratories Recent Developments/Updates
Table 125. Amgen Corporation Information
Table 126. Amgen Description and Business Overview
Table 127. Amgen Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Amgen Biosimilars Product
Table 129. Amgen Recent Developments/Updates
Table 130. Celltrion Corporation Information
Table 131. Celltrion Description and Business Overview
Table 132. Celltrion Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Celltrion Biosimilars Product
Table 134. Celltrion Recent Developments/Updates
Table 135. Samsung Biologics Corporation Information
Table 136. Samsung Biologics Description and Business Overview
Table 137. Samsung Biologics Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. Samsung Biologics Biosimilars Product
Table 139. Samsung Biologics Recent Developments/Updates
Table 140. Roche Corporation Information
Table 141. Roche Description and Business Overview
Table 142. Roche Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 143. Roche Biosimilars Product
Table 144. Roche Recent Developments/Updates
Table 145. Probiomed Corporation Information
Table 146. Probiomed Description and Business Overview
Table 147. Probiomed Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 148. Probiomed Biosimilars Product
Table 149. Probiomed Recent Developments/Updates
Table 150. Apotex Corporation Information
Table 151. Apotex Description and Business Overview
Table 152. Apotex Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 153. Apotex Biosimilars Product
Table 154. Apotex Recent Developments/Updates
Table 155. Chong Kun Dang Corporation Information
Table 156. Chong Kun Dang Description and Business Overview
Table 157. Chong Kun Dang Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 158. Chong Kun Dang Biosimilars Product
Table 159. Chong Kun Dang Recent Developments/Updates
Table 160. JCR Pharmaceuticals Corporation Information
Table 161. JCR Pharmaceuticals Description and Business Overview
Table 162. JCR Pharmaceuticals Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 163. JCR Pharmaceuticals Biosimilars Product
Table 164. JCR Pharmaceuticals Recent Developments/Updates
Table 165. Gan & Lee Pharmaceuticals Corporation Information
Table 166. Gan & Lee Pharmaceuticals Description and Business Overview
Table 167. Gan & Lee Pharmaceuticals Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 168. Gan & Lee Pharmaceuticals Biosimilars Product
Table 169. Gan & Lee Pharmaceuticals Recent Developments/Updates
Table 170. Gedeon Richter Corporation Information
Table 171. Gedeon Richter Description and Business Overview
Table 172. Gedeon Richter Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 173. Gedeon Richter Biosimilars Product
Table 174. Gedeon Richter Recent Developments/Updates
Table 175. Biocad Corporation Information
Table 176. Biocad Description and Business Overview
Table 177. Biocad Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 178. Biocad Biosimilars Product
Table 179. Biocad Recent Developments/Updates
Table 180. Coherus Bioscience Corporation Information
Table 181. Coherus Bioscience Description and Business Overview
Table 182. Coherus Bioscience Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 183. Coherus Bioscience Biosimilars Product
Table 184. Coherus Bioscience Recent Developments/Updates
Table 185. Stada Arzneimittel AG Corporation Information
Table 186. Stada Arzneimittel AG Description and Business Overview
Table 187. Stada Arzneimittel AG Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 188. Stada Arzneimittel AG Biosimilars Product
Table 189. Stada Arzneimittel AG Recent Developments/Updates
Table 190. Key Raw Materials Lists
Table 191. Raw Materials Key Suppliers Lists
Table 192. Biosimilars Distributors List
Table 193. Biosimilars Customers List
Table 194. Biosimilars Market Trends
Table 195. Biosimilars Market Drivers
Table 196. Biosimilars Market Challenges
Table 197. Biosimilars Market Restraints
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biosimilars
Figure 2. Global Biosimilars Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Biosimilars Market Share by Type in 2024 & 2034
Figure 4. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Product Picture
Figure 5. Recombinant Glycosylated Proteins Product Picture
Figure 6. Global Biosimilars Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Biosimilars Market Share by Application in 2024 & 2034
Figure 8. Oncology
Figure 9. Blood Disorders
Figure 10. Growth Hormonal Deficiency
Figure 11. Chronic and Autoimmune Disorders
Figure 12. Others
Figure 13. Global Biosimilars Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Biosimilars Market Size (2018-2034) & (US$ Million)
Figure 15. Global Biosimilars Sales (2018-2034) & (K Units)
Figure 16. Global Biosimilars Average Price (USD/Unit) & (2018-2034)
Figure 17. Biosimilars Report Years Considered
Figure 18. Biosimilars Sales Share by Manufacturers in 2024
Figure 19. Global Biosimilars Revenue Share by Manufacturers in 2024
Figure 20. The Global 5 and 10 Largest Biosimilars Players: Market Share by Revenue in 2024
Figure 21. Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 22. Global Biosimilars Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 23. North America Biosimilars Sales Market Share by Country (2018-2034)
Figure 24. North America Biosimilars Revenue Market Share by Country (2018-2034)
Figure 25. U.S. Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Canada Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 27. Europe Biosimilars Sales Market Share by Country (2018-2034)
Figure 28. Europe Biosimilars Revenue Market Share by Country (2018-2034)
Figure 29. Germany Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. France Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. U.K. Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Italy Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Russia Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Asia Pacific Biosimilars Sales Market Share by Region (2018-2034)
Figure 35. Asia Pacific Biosimilars Revenue Market Share by Region (2018-2034)
Figure 36. China Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Japan Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. South Korea Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. India Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Australia Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. China Taiwan Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Indonesia Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Thailand Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Malaysia Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Latin America Biosimilars Sales Market Share by Country (2018-2034)
Figure 46. Latin America Biosimilars Revenue Market Share by Country (2018-2034)
Figure 47. Mexico Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Brazil Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Argentina Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Middle East & Africa Biosimilars Sales Market Share by Country (2018-2034)
Figure 51. Middle East & Africa Biosimilars Revenue Market Share by Country (2018-2034)
Figure 52. Turkey Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Saudi Arabia Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. UAE Biosimilars Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Global Sales Market Share of Biosimilars by Type (2018-2034)
Figure 56. Global Revenue Market Share of Biosimilars by Type (2018-2034)
Figure 57. Global Biosimilars Price (USD/Unit) by Type (2018-2034)
Figure 58. Global Sales Market Share of Biosimilars by Application (2018-2034)
Figure 59. Global Revenue Market Share of Biosimilars by Application (2018-2034)
Figure 60. Global Biosimilars Price (USD/Unit) by Application (2018-2034)
Figure 61. Biosimilars Value Chain
Figure 62. Biosimilars Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed